1. Prognostic assessment: p16INK4A serves as a potential favorable prognostic marker, particularly in analyses related to the immune microenvironment.2. Treatment development: This study provides new insights for immunotherapy strategies, such as developing combination therapies that induce senescence in tumor cells followed by the activation of antitumor immunity. Here, CDKN2A is linked to neoplasm.